Patents Examined by Vanessa L. Ford
  • Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
    Patent number: 9132177
    Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC).
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: September 15, 2015
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Alpha lactalbumin immunization methods
    Patent number: 9125848
    Abstract: Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human ?-lactalbumin.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: September 8, 2015
    Assignee: The Cleveland Clinic Foundation
    Inventors: Vincent K. Tuohy, Justin M. Johnson, Ritika Jaini
  • Antibodies to the B12-transcobalamin receptor
    Patent number: 9120858
    Abstract: The present invention provides anti-TCblR antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: September 1, 2015
    Assignee: The Research Foundation of State University of New York
    Inventors: Edward V. Quadros, Jeffrey M. Sequeira
  • Treatment of degenerative joint disease
    Patent number: 9060968
    Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: June 23, 2015
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, James V. Winkler
  • Anti-fibroblast activation protein antibodies and methods and uses thereof
    Patent number: 8999342
    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: April 7, 2015
    Assignee: Ludwig Institute for Cancer Research, Ltd.
    Inventors: Christoph Renner, Eliane Fischer, Stefan Bauer, Thomas Wüest
  • Modified SAK gene for the production of recombinant proteins
    Patent number: 8853380
    Abstract: The present invention relates to modified SAK gene having amino acid SEQ ID 2. The present invention further relates to process for cloning and expressing modified SAK gene fusion protein which imparts improved stability to the heterologous protein of interest. Further the invention relates to process of purification of recombinant heterologous proteins from bacterial inclusion bodies using modified SAK.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: October 7, 2014
    Assignee: Lupin Limited
    Inventors: Shardul Salunkhe, Bhaskarjyoti Prasad, Praveen Muneshwar, Anjali Apte Deshpande, Sriram Padmanabhan
  • Methods of use of probiotic for companion animals
    Patent number: 8802158
    Abstract: According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Lactobacilli.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: August 12, 2014
    Assignees: The Iams Company, Alimentary Health, Ltd.
    Inventors: Thomas William-Maxwell Boileau, Michael Anthony Ceddia, Gary Mitchell Davenport, Barry Pius Kiely, Liam Diarmuid O'Mahony, Gregory Dean Sunvold, Mark Alan Tetrick, Robert Jason Vickers
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 8795669
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: August 5, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott Walsh, Daniel Dix
  • Methods for treating refractory infections in neutropenic individuals
    Patent number: 8790662
    Abstract: The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by bacteria, fungi, protozoa, and viruses. The methods of the invention represent a practical, rapid cell-based immunotherapy for refractory infections comprising compositions of activated, irradiated HL-60 cells.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: July 29, 2014
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Brad J. Spellberg, Ashraf S. Ibrahim, John E Edwards, Jr.
  • vaccines
    Patent number: 8784829
    Abstract: The present invention relates to polynucleotide sequences encoding novel Lawsonia intracellularis polypeptides. It also relates to DNA fragments, recombinant plasmid DNA and live recombinant microorganisms comprising these sequences. Moreover, the invention relates to polypeptides encoded by these nucleotide sequences. The invention also relates to immunogenic compositions for prevention of Lawsonia intracellularis infections and methods for the preparation of these immunogenic compositions. The invention also relates to diagnostic tests for the detection of Lawsonia intracellularis DNA, the detection of Lawsonia intracellularis antigens and detection of antibodies against Lawsonia intracellularis.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: July 22, 2014
    Assignee: Intervet Inc.
    Inventors: Mohamad A. Morsey, Stephanie M. Cook, Yuanzheng Zhang, Qing Zhang
  • Methods for determining personalized treatment compositions for prostate cancer and breast cancer
    Patent number: 8784795
    Abstract: The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: July 22, 2014
    Assignee: Caldera Health Limited
    Inventors: James D. Watson, Richard Llewellyn Sydney Forster
  • Methods and compositions for diagnosis and prognosis of renal injury and renal failure
    Patent number: 8778615
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: July 15, 2014
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura
  • Microfluidized oil-in-water emulsions and vaccine compositions
    Patent number: 8771727
    Abstract: This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: July 8, 2014
    Assignee: Zoetis LLC
    Inventors: Paul J. Dominowski, Ramasamy M. Mannan, Richard L. Krebs, Pamela K. Klose
  • Oral glucagon-like peptide conjugates for metabolic diseases
    Patent number: 8759290
    Abstract: The present invention relates to the field of metabolic compound conjugates, methods of forming said conjugates and uses of these conjugates in the treatment of diabetes and conditions related to this condition. The metabolic compound conjugates of this invention include a metabolic peptide having a glucagon-like peptide (GLP-1) receptor binding motif for action on a GLP-1 receptor and at least one oligomer conjugation site for binding with at least one oligomer, wherein the oligomer includes a polyethylene glycol moiety (PEG), and/or alkyl moiety.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: June 24, 2014
    Assignee: Biocon Limited
    Inventor: Kenneth D. James
  • Monoclonal antibodies to anthrax protective antigen
    Patent number: 8753635
    Abstract: The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a Bacillus anthracis infection. The monoclonal antibodies bind to a specific region comprising amino acids 311-316 of PA, ASFFDI or a larger fragment comprising amino acids 301-330 of PA, SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. Vaccines comprising these peptides may be used to immunize individuals against Bacillus anthracis infection.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: June 17, 2014
    Inventors: Raymond Tsang, Jody Berry, Xin Yuan, Cindi Corbett, Mike Gubbins, Amin Kabani, Lisa Schmidt
  • Capsular polysaccharide solubilisation and combination vaccines
    Patent number: 8753651
    Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from the serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: June 17, 2014
    Assignee: Novartis AG
    Inventor: Paolo Costantino
  • Pharmaceutical compositions
    Patent number: 8748377
    Abstract: The present invention provides pharmaceutical compositions comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg, 30 mg, 50 mg or 100 mg of said polypeptide having GLP-1 activity. Also provided are methods of administering the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: June 10, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Bush, Murray W. Stewart, Yonghong Yang
  • Inactivating pathogens with oxidizing agents for vaccine production
    Patent number: 8716000
    Abstract: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: May 6, 2014
    Assignee: Oregon Health and Science University
    Inventors: Mark K. Slifka, Shirley Villadiego, Erika Hammarlund, Paul Yoshihara
  • Compositions and methods for activating innate and allergic immunity
    Patent number: 8709447
    Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: April 29, 2014
    Assignee: ID Biomedical Corporation of Quebec
    Inventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
  • Anti-GITR antibodies
    Patent number: 8709424
    Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: April 29, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta